It is poorly understood why there is greater cardiovascular disease risk associated with the apolipoprotein E4 (apoE) allele vs. apoE3, and also greater risk with the LRP8/apolipoprotein E receptor 2 (ApoER2) variant ApoER2-R952Q. Little is known about the function of the apoE-ApoER2 tandem outside of the central nervous system. We now report that in endothelial cells apoE3 binding to ApoER2 stimulates endothelial NO synthase (eNOS) and endothelial cell migration, and it also attenuates monocyte-endothelial cell adhesion. However, apoE4 does not stimulate eNOS or endothelial cell migration or dampen cell adhesion, and alternatively it selectively antagonizes apoE3/ApoER2 actions. The contrasting endothelial actions of apoE4 vs. apoE3 require the N-terminal to C-terminal interaction in apoE4 that distinguishes it structurally from apoE3. Reconstitution experiments further reveal that ApoER2-R952Q is a loss-of-function variant of the receptor in endothelium. Carotid artery reendothelialization is decreased in ApoER2 −/− mice, and whereas adenoviraldriven apoE3 expression in wild-type mice has no effect, apoE4 impairs reendothelialization. Moreover, in a model of neointima formation invoked by carotid artery endothelial denudation, ApoER2
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−/− mice display exaggerated neointima development. Thus, the apoE3/ ApoER2 tandem promotes endothelial NO production, endothelial repair, and endothelial anti-inflammatory properties, and it prevents neointima formation. In contrast, apoE4 and ApoER2-R952Q display dominant-negative action and loss of function, respectively. Thus, genetic variants of apoE and ApoER2 impact cardiovascular health by differentially modulating endothelial function.
C ardiovascular disease risk is modified by common genetic variants of apolipoprotein E (apoE) and its receptor apolipoprotein E receptor 2 (ApoER2), which is a member of the LDL receptor family. Compared with the most common allele apoE3, individuals with the apoE4 allele have an increased risk of atherosclerosis and coronary heart disease (1, 2). The LRP8 gene, which encodes ApoER2, is a major gene locus for premature atherosclerosis and acute myocardial infarction identified in four independent human populations. In particular, homozygous carriers of the ApoER2-R952Q variant have a twofold increased risk of these conditions (3) (4) (5) . ApoER2-R952Q also has an additive effect with apoE4, with the combined genotype QQ/E4 showing a 3.9-fold greater susceptibility to cardiovascular disease (5) . ApoER2 polymorphism-associated risk is independent of cholesterol levels (3) (4) (5) , and although apoE4 may impact LDL abundance (2) , there is also evidence that apoE4-associated risk goes well beyond changes in lipoprotein status (6) (7) (8) (9) . Whereas there is considerable understanding of the biology of the apoE-ApoER2 tandem in the central nervous system and in Alzheimer's disease (10) , the basis for the cardiovascular impact of the receptor and apoE variants remains unclear.
Our prior work demonstrated that ApoER2 is expressed in endothelial cells, where it plays a critical role in the pathogenesis of the antiphospholipid syndrome (APS) (11) . The receptor is enriched in caveolae/lipid rafts in which signaling molecules regulating endothelial NOS (eNOS) are compartmentalized (12, 13) . We now know that in APS, antiphospholipid antibody recognition of the cell surface protein β2-GPI on endothelial cells promotes β2-GPI dimerization and interaction with the extracellular domain of ApoER2, causing the activation of PP2A and eNOS antagonism. The resulting decrease in bioavailable NO underlies APS-related thrombosis (11) . However, the normal function of the receptor in endothelium, and whether and how it modulates apoE actions on endothelium, are unknown.
In addition to regulating thrombogenesis, eNOS-derived NO plays a major role in cardiovascular protection via promotion of the integrity of the endothelial cell monolayer and attenuation of endothelial cell-leukocyte adhesion (13) . Recognizing that eNOS enzymatic activity is both positively and negatively modulated by signaling molecules in endothelial caveolae/lipid rafts (14) , to better understand the biology of ApoER2 in endothelium we hypothesized that apoE3 binding to the receptor activates eNOS. Experiments were performed in cell culture and in mice to test this hypothesis and to determine whether genetic variants in apoE or ApoER2 disrupt this process and thereby adversely impact endothelial function.
Results
ApoE3, ApoER2, and Endothelial Cell Function. To determine whether apoE3 stimulates eNOS enzymatic activity, 14 C-L-arginine conversion to 14 C-L-citrulline was measured in intact bovine aortic endothelial cells (BAECs) incubated with vehicle or apoE3 for 15 min. ApoE3 at a concentration of 15 μg/mL caused a nearly twofold increase in eNOS enzymatic activity (Fig. 1A) . The degree of eNOS activation Significance Why genetic variants of the circulating protein apolipoprotein E (apoE) or its receptor apoliprotein E receptor 2 (ApoER2) confer greater cardiovascular disease risk is poorly understood. We report that in endothelial cells, which are the guardian cells of the vascular wall, the most common form of apoE, apoE3, activates ApoER2 to favorably impact endothelial function. The riskenhancing apoE variant apoE4 lacks this capacity and instead inhibits apoE3-ApoER2 action, and a risk-conferring ApoER2 variant is nonfunctional in endothelium. Evidence is obtained in mice that the genetic variants adversely impact endothelial repair and related vascular disease severity. From these discoveries personalized treatment strategies may be developed to protect individuals with risk-altering apoE or ApoER2 variants, which comprise approximately 15% of the population.
caused by apoE3 was comparable to that observed with the classic eNOS agonist VEGF, and concurrent cell treatment with VEGF and apoE3 did not increase eNOS activity beyond that observed with either agent alone (Fig. 1B) . In human aortic endothelial cells (HAECs) apoE3 also activated the eNOS enzyme (Fig. S1 ). These findings are consistent with the previous observations that apoE3 promotes NO release from human umbilical vein endothelial cells and from EA.hy926 endothelial-epithelial hybrid cells (15, 16) . A key role for ApoER2 in the apoE3 mechanism of action in endothelial cells was then demonstrated for the first time (to our knowledge) by the finding that siRNA-based depletion of the receptor in BAEC (Fig. 1C) fully attenuated eNOS activation by the apolipoprotein (Fig. 1D) . In contrast, in cells devoid of ApoER2, eNOS stimulation by VEGF remained intact, indicating that ApoER2 is uniquely necessary for apoE3 stimulation of eNOS.
The impact of apoE3 on endothelial cell migration was also tested, using scratch assays. ApoE3 caused a fivefold stimulation in endothelial cell migration (Fig. 1E) . The participation of eNOS in apoE3 stimulation of cell migration was demonstrated by the finding that the migration response was fully prevented by the NOS antagonist nitro-L-arginine methyl ester (L-NAME) (Fig. 1F) . In additional experiments, the stimulation of migration by apoE3 was evaluated in endothelial cells expressing or lacking ApoER2. Whereas siRNA-mediated knockdown of the receptor attenuated the migration prompted by apoE3, migration stimulated by VEGF was unaffected (Fig. 1G) . Thus, apoE3 activates endothelial cell migration, and this is mediated by ApoER2 and by eNOS.
Having demonstrated beneficial reparative processes invoked by apoE3 and ApoER2 in endothelial cells, how the tandem may influence inflammatory processes was evaluated in studies of endothelial cell-monocyte adhesion in culture. LPS predictably caused increased adhesion in control siRNA-treated cells, and apoE3 reversed the LPS-induced adhesion ( Fig. 2A, Left) . In contrast, in cells depleted of ApoER2, the increase in adhesion invoked by LPS was unaffected by the addition of apoE3 ( Fig. 2A, Right) . Summary data revealed that in control siRNA-treated cells there was a sixfold increase in adhesion prompted by LPS, which was attenuated 66% by apoE3 (Fig. 2B) ; in contrast, there was no decline in LPS-induced adhesion by apoE3 in cells deficient in ApoER2. The decline in adhesion caused by apoE3 was fully reversed by L-NAME ( Fig. 2 C and D) . Thus, via eNOS the apoE3-ApoER2 tandem is antiadhesive.
ApoER2-R952Q Function in Endothelial Cells. To determine whether a genetic variant of ApoER2 demonstrated to impact the risk of cardiovascular disease alters the function of the receptor in endothelial cells, eNOS activation by wild-type ApoER2 and ApoER2-R952Q was compared. The first approach entailed the cotransfection of eNOS and forms of ApoER2 in NIH 3T3 cells, which express negligible endogenous ApoER2 or eNOS. Equal expression of the two receptor constructs and of eNOS, and equal basal NOS activity were confirmed ( Fig. 3 A and B) . Whereas apoE3 did not stimulate NOS activity beyond basal levels in sham-transfected cells deficient in ApoER2 (Fig. 3C ), wild-type ApoER2-expressing cells displayed a threefold increase in enzyme activation in response to apoE3; in contrast, in cells expressing ApoER2-R952Q there was no activation of eNOS by apoE3.
Having observed differential activity of wild-type ApoER2 and ApoER2-R952Q in 3T3 cells, their functions in endothelial cells were then compared by siRNA knockdown of the endogenous receptor in BAEC followed by reconstitution with one of the two constructs (Fig. 3D ). There was a disparity in the molecular weights of endogenous vs. exogenous ApoER2, probably explained by differences in splice variants (17) , and the observed doublet likely reflects receptor glycosylation (18, 19) . In endothelial cells lacking ApoER2, apoE3 did not stimulate eNOS activity above basal levels (Fig. 3E ). In contrast, there was a twofold increase in eNOS activity in response to apoE3 in cells in which endogenous ApoER2 was replaced with wild-type ApoER2. However, in cells expressing ApoER2-R952Q, apoE3 did not cause an increase in eNOS activation above basal levels. These findings confirm the requirement for ApoER2 in apoE3 activation of eNOS, and more importantly they reveal that the ApoER2-R952Q variant is a loss-of-function variant in endothelial cells.
ApoE4 Action on Endothelial Cells. ApoE3 and apoE4 actions were initially compared in studies of eNOS activation in BAECs (Fig.  4A ). Whereas apoE3 stimulated enzyme activity, apoE4 did not, explaining prior findings for NO release by apoE3 vs. apoE4 in EA.hy926 endothelial-epithelial hybrid cells (16) . The impact of apoE4 on apoE3-induced eNOS activity was also investigated. The concurrent addition of apoE4 to apoE3-treated endothelial cells antagonized apoE3-related eNOS activity, and this was After transfection with control siRNA or siRNA targeting ApoER2, eNOS activation was evaluated in BAECs treated with VEGF (100 ng/mL) or apoE3 (15 μg/mL). (E) In scratch assays BAECs were wounded and treated with control media alone or 0.5-15 μg/mL apoE3 for 16 h, and cell migration was quantified. Representative images for control and 15 μg/mL apoE3 treatment are shown in Inset. (F) Scratch assays were performed in BAECs in the absence vs. presence of apoE3 (15 μg/mL), using cells concomitantly treated with vehicle or L-NAME (2 mM). (G) Scratch assays were done with or without treatment with VEGF (100 ng/mL) or apoE3 (15 μg/mL) in BAECs previously transfected with control siRNA or siRNA targeting ApoER2. In A and B and D-G, values are mean ± SEM, n = 6-8, *P < 0.05 vs. basal, † P < 0.05 vs. Con siRNA or no L-NAME.
apparent at less than equimolar concentrations of the apolipoproteins (Fig. 4B ). Studies in HAECs yielded similar results (Fig.  S2 ). Whereas apoE4 attenuated eNOS activation by apoE3, it had no effect on eNOS stimulation by VEGF (Fig. 4C) . Thus, apoE4 antagonizes apoE3 activation of eNOS, the action of apoE4 is specific to eNOS stimulation by apoE3, and this process occurs in both bovine and human endothelial cells.
Having observed disparate actions of apoE3 and apoE4 on eNOS, studies of endothelial cell migration were then performed. Whereas apoE3 caused cell migration comparable to that occurring in response to VEGF, apoE4 alone had no effect (Fig. 4D) . Although apoE4 did not impact VEGF-induced migration, apoE4 fully blocked the stimulation of endothelial cell migration by apoE3. In addition, apoE4 blunted apoE3 attenuation of endothelial cell-monocyte adhesion (Fig. S3) . Interestingly, the findings that apoE4 antagonizes the favorable effects of apoE3 on eNOS, endothelial cell migration, and adhesion are consistent with the clinical observation that cardiovascular disease risk is increased not only in individuals homozygous for apoE4 but also in heterozygous subjects (1) .
To determine how apoE4 antagonizes apoE3 action, the kinases involved in apoE3/ApoER2 activation of eNOS were identified. Mirroring their effects on the response to VEGF, both PI3 kinase antagonism with LY294002 and Src kinase antagonism with PP2 fully prevented eNOS activation by apoE3-ApoER2 (Fig. 4E) . The ability of apoE4 to inhibit PI3 kinase/Akt activation by apoE3 was then tested by examining Ser473 phosphorylation of Akt. Similar to the positive control agonist VEGF (Fig. 4 F and G, Left), apoE3 caused phosphorylation of Akt (Fig. 4 F and G,  Right) , and the addition of apoE4 attenuated apoE3 activation of Akt. Therefore, apoE4 blunts kinase activation by apoE3-ApoER2 in endothelial cells, and this is likely the basis for apoE4 antagonism of the activation of eNOS and endothelial cell migration by the ligand-receptor tandem.
To gain additional understanding of the apoE4 mechanism of action, a comparison was made between the effects on apoE3-stimulated eNOS activity of wild-type apoE4 vs. a truncated form of apoE4 composed of the N-terminal two-thirds of the molecule (residues 1-191, designated T-apoE4) generated by thrombin digestion. The 22-kDa truncated fragment of apoE lacks the C terminus of the protein, thereby disrupting the N-to C-terminal interaction in apoE4, but receptor binding remains intact (20) . Whereas full-length apoE4 antagonized eNOS activation by apoE3 in BAEC, C-terminally truncated apoE4 did not (Fig.  4H) . Identical observations were made in HAECs (Fig. 4I) . The capacities of both C-terminally truncated apoE3 and apoE4 to activate eNOS were also evaluated, and in contrast to full-length apoE4, they stimulated eNOS and did so to a comparable degree (Fig. 4J) . These findings suggest that the N-to C-terminal interaction in apoE4 is required for both its loss-of-function and dominant-negative effect on apoE3 action in endothelial cells.
ApoE, ApoER2, and Reendothelialization in Vivo. Having observed that the apoE3-ApoER2 tandem promotes the migration of cultured endothelial cells, we sought to determine whether comparable processes are operative in vivo. Because apoE deletion in mice causes hypercholesterolemia that can alter endothelial cell function through numerous mechanisms, we alternatively accomplished loss of function via deletion of ApoER2 and compared carotid artery reendothelialization after perivascular electric injury in ApoER2 (C) NOS activity was determined in the three study groups in the absence (basal) or presence of apoE3 (15 μg/mL). Results for apoE3-stimulated activity are expressed as the percentage of basal activity. In B and C, values are mean ± SEM, n = 6-8; *P < 0.05 vs. sham. (D) Reconstitution experiments were performed in BAECs. Endogenous ApoER2 was down-regulated using siRNA directed against bovine ApoER2, and sham, WT ApoER2, or ApoER2-R952Q cDNA were introduced. ApoER2 abundance was then evaluated at 24 h by immunoblot analysis. (E) NOS activity was determined in the three study groups in D, in the absence (basal) or presence of apoE3 (15 μg/mL). Results for apoE3-stimulated activity are expressed as percentage of basal activity. Values are mean ± SEM, n = 12, *P < 0.05 vs. sham.
vs. ApoER2
−/− mice. After endothelium removal, the area of denudation remaining 72 h later was evaluated by assessing the uptake of Evans blue dye by the intimal surface (Fig. 5A) . In contrast to the carotid arteries of ApoER2 +/+ mice, which showed minimal Evans blue dye uptake 72 h after denudation, indicating effective endothelial monolayer repair, the carotid arteries of ApoER2 −/− mice displayed sixfold greater remaining area of denudation (Fig. 5  A and B) . Thus, ApoER2 plays an important role in endothelial repair in vivo.
In preparation for in vivo experiments using human apoE in mice, the impact of apoE3 on migration by mouse primary aortic endothelial cells was evaluated (Fig. S4) . With an effect that was at least as great as that of VEGF, apoE3 caused a fourfold increase in migration by the mouse endothelial cells. The impact of the ApoER2 ligands apoE3 and apoE4 on endothelial repair was then evaluated in vivo in mice. Carotid artery reendothelialization was compared in wild-type mice previously given tail vein injections of second-generation adenoviral constructs encoding lacZ (negative control), human apoE3, or human apoE4. As previously mentioned, there is an N-and C-terminal domain interaction in apoE4 that is lacking in apoE3 (21) . Mice express a single form of apoE in which domain interactions do not occur, and mouse apoE behaves like human apoE3 (22) . Mice administered lacZ-encoding adenovirus, therefore expressing only mouse apoE, displayed essentially full reendothelialization 72 h after denudation (Fig. 5C) . Similarly, mice administered adenovirus encoding human apoE3 had minimal areas of remaining denudation. In contrast, mice who received adenovirus encoding human apoE4 had large remaining areas of denudation, phenocopying the impact of ApoER2 loss of function on reendothelialization. Summary data revealed that human apoE4 expression resulted in fivefold greater remaining area of denudation compared with apoE3 (Fig. 5D) . Thus, paralleling the ex vivo findings (Fig. 4D) , apoE4 blunted reendothelialization in mice, indicating that apoE4 has a detrimental impact on endothelial function in vivo.
ApoER2 and Neointima Formation. To determine whether ApoER2-mediated endothelial repair affords protection from vascular disease in vivo, we studied a mouse model of carotid artery neointima development that occurs in response to endothelial denudation independent of medial layer damage (23, 24) . Experiments were performed in FVB/N mice because in contrast to C57BL/6, 
(B) eNOS activation was evaluated in
BAECs in the presence of apoE3 at 15 μg/mL, with 0-10 μg/mL of apoE4 added (n = 4). (C ) eNOS activation was evaluated in BAECs in the absence vs. presence of apoE3 (15 μg/mL) or VEGF (100 ng/mL), with or without 15 μg/mL apoE4 added (n = 13). (D) In scratch assays BAECs were wounded and treated with control media alone, VEGF (100 ng/mL), apoE3 (15 μg/mL), apoE4 (15 μg/mL), VEGF plus apoE4, or apoE3 plus apoE4 for 16 h, and cell migration was evaluated (n = 4). For A-D, values are mean ± SEM, *P < 0.05 vs. basal, † P < 0.05 vs. apoE3 only. (E ) eNOS activation by VEGF (100 ng/mL) or apoE3 (15 μg/mL) was evaluated in BAECs preincubated with vehicle, the PI3 kinase inhibitor LY294002 (50 μM for 60 min), or the Src family kinase inhibitor PP2 (10 μM for 15 min). Values are mean ± SEM, *P < 0.05 vs. VEGF only, † P < 0.05 vs. apoE3 only (n = 3). (F )
Changes in Akt phosphorylation were evaluated in BAECs in response to VEGF (100 ng/mL), apoE3 (15 μg/mL), or apoE3 plus apoE4 (15 μg/mL) added for the durations shown. Cells were treated, and immunoblotting was performed on cell lysates to quantify phospho-Akt-Ser473 and total Akt. Representative immunoblots are shown. (G) Summary data for three to four experiments. Values are mean ± SEM, *P < 0.05 vs. basal. (H) eNOS activation was evaluated in BAECs in the presence of 15 μg/mL of apoE3, without or with 5 μg/mL full-length apoE4 or truncated apoE4 (T-apoE4) added. (I) eNOS activation was evaluated in HAECs in the presence of 5 μg/mL apoE3, without or with 1 μg/mL full-length apoE4 or truncated apoE4 (T-apoE4) added. (J) eNOS activation was evaluated in HAECs in the presence of 5 μg/mL full-length apoE3, truncated apoE3 (T-apoE3), full-length apoE4, or truncated apoE4 (T-apoE4). For H-J, values are mean ± SEM, n = 6, *P < 0.05 vs. apoE3 only, † P < 0.05 vs. apoE4. endothelium removal in FVB/N causes neointima formation under normocholesterolemic conditions (24) . In sham-operated, nondenuded arteries, vessel architecture was similar in ApoER2 +/+ vs. ApoER2 −/− mice ( Fig. 6 A and B, respectively) . In previously denuded arteries, there was dramatically more neointima formation in ApoER2 −/− vs. ApoER2
, and this was evident either in sections stained with Verhoeff Van-Gieson to visualize the elastic laminae ( Fig. 6 C and D) or in hematoxylin and eosin-stained sections (Fig.  6 E and F) . Summary data revealed that there was 2.5-fold greater intima-to-media ratio in ApoER2 −/− vs. ApoER2 +/+ (Fig. 6G ) and threefold greater neointima area in ApoER2 −/− vs. ApoER2 +/+ (Fig. 6H) . Total cholesterol and triglyceride levels were similar in ApoER2 +/+ and ApoER2 −/− mice (respectively, 79 ± 7 vs. 64 ± 10 mg/dL for cholesterol, and 79 ± 12 vs. 65 ± 16 mg/dL for triglyceride; n = 6, P = nonsignificant), consistent with ApoER2 not being expressed in the liver and not participating in global cholesterol homeostasis (19) . As such, the blunted reendothelialization and the exaggerated neointima development prompted by endothelial removal in ApoER2 −/− mice are not related to changes in circulating lipid levels. The cumulative in vivo findings indicate that there is an adverse impact on the processes that maintain endothelial monolayer integrity by either apoE4 or by ApoER2 loss of function, such as with the ApoER2-R952Q variant, and that the resulting attenuation of the capacity for endothelial repair can promote vascular disorders such as neointima formation.
Discussion
There is greater cardiovascular disease risk associated with the apoE4 allele vs. apoE3, and also with the ApoER2 variant ApoER2-R952Q, and there is evidence that the increased disease predisposition may be related to mechanisms other than changes in lipid status (3) (4) (5) (6) (7) (8) (9) . How ApoER2 and its interactive actions with apoE potentially influence the behavior of endothelial cells, which are critically involved in vascular health and disease, has been unknown. We now report that via ApoER2 and PI3 kinase/Akt, apoE3 stimulates eNOS and endothelial cell migration, and it also attenuates leukocyte-endothelial cell adhesion. In contrast, apoE4 does not stimulate eNOS or endothelial cell migration or dampen cell adhesion, and instead it antagonizes apoE3/ApoER2 actions. In addition, we have demonstrated that ApoER2-R952Q is nonfunctional in endothelial cells. Thus, apoE3 actions via wild-type ApoER2 have beneficial effects on the endothelium, and genetic variants of apoE and ApoER2 differentially modulate endothelial function.
In vivo experiments revealed that ApoER2 loss of function results in marked attenuation of the capacity for reendothelialization. The further observation that ApoER2 deletion results in greater neointima formation invoked by endothelial monolayer disruption independent of medial layer injury demonstrates how attenuated endothelial ApoER2 function, such as with ApoER2-R952Q, would contribute to vascular disease pathogenesis. The in vivo implications of the dominant-negative action of apoE4 on endothelium were demonstrated by the finding that apoE4 expression and not apoE3 expression in mice attenuated carotid artery endothelial repair.
Although direct extrapolation to the clinical setting should be done with caution, the dominant-negative actions of apoE4 on apoE3-induced processes in endothelium that we have shown are consistent with the observation that individuals heterozygous as well as homozygous for apoE4 display increased cardiovascular disease risk (1) . Because the dominant-negative actions of apoE4 were specific to apoE3-initiated, ApoER2-dependent processes, and upstream Akt activation was attenuated in parallel with apoE4 antagonism of eNOS and its effects on cell migration and adhesion, the causal event(s) most likely involves differential direct actions of apoE4 and apoE3 on ApoER2. Because the dominantnegative influence of apoE4 was observed at concentrations that were up to an order of magnitude lower than those of apoE3, and apoE3 and apoE4 have similar affinity to LDL receptor family members including ApoER2 (25, 26) , competitive binding to ApoER2 is not likely the underlying mechanism. Competitive binding is also unlikely because we demonstrated that a C-terminally truncated form of apoE4 generated by thrombin digestion, which yields a 22-kDa fragment that retains normal receptor binding but lacks the N-to C-terminal interaction characteristic of apoE4 (27) , is incapable of inhibiting eNOS activation in response to apoE3; alone the truncated form of apoE4 actually stimulates eNOS in a manner mirroring the actions of apoE3. These observations suggest that the N-to C-terminal interaction in apoE4 is required for both its loss of function and its dominant-negative effect on apoE3-induced responses in endothelial cells. One possibility is that the binding of full-length apoE4 may cause a unique conformational change in ApoER2 that alters the signaling function of the receptor in endothelium, perhaps by disturbing its interaction with other proteins. The identification of potential partner molecules required for the apoE3-ApoER2 tandem to modulate endothelial cell function is now warranted.
In the first investigation of ApoER2-R952Q and cardiovascular disease risk, the association of the SNP with greater risk was apparent in family studies but not in sporadic, late-onset myocardial infarction populations (3). A follow-up family study as well as an inquiry in a separate myocardial infarction/coronary artery disease cohort failed to show the association. However, in the latter work the cases were ∼10 y older than in the original report, and it has been concluded that the ApoER2-R952Q variant is primarily relevant to early-onset cardiovascular disease (28) . Interestingly, HapMap data recently revealed that the R952Q SNP resides in the fifth of five linkage disequilibrium (LD) or haplotype blocks at the C terminus of the gene, designated LD5. Mirroring the findings for R952Q, four additional SNPs in LD5 display association with familial and early-onset coronary artery disease and/or myocardial infarction. However, a common haplotype of LD5, TCCGC, has also been discovered that is highly associated with protection from the development of familial and early-onset coronary artery disease and/or myocardial infarction, with odds ratios of 0.53, 0.42, and 0.71 in three different cohorts (29) . These recent genetic observations in combination with the present discovery of a major protective role for ApoER2 in endothelium strengthen the candidacy of LRP8 as an important cardiovascular disease risk gene. Up until now there has been scant understanding of the biology of the apoE-ApoER2 tandem outside of the central nervous system (10) . The present work has revealed a previously unidentified series of mechanisms by which apoE3 and ApoER2 are positive modulators of endothelial cell NO production, endothelial cell repair, and endothelial cell antiadhesive properties. We have further demonstrated that apoE4 has a dominantnegative effect on the processes mediated by the ApoE3/ ApoER2 tandem in endothelium, that ApoER2-R952Q is a lossof-function variant of the receptor in endothelium, and that either apoE4 or ApoER2 loss of function adversely impacts the processes that maintain endothelial monolayer integrity and related vascular disease severity in vivo. These discoveries provide a paradigm in which the effects of genetic variants of apoE and ApoER2 on vascular health can be better understood. In addition, the new information gained may aid in the development of personalized treatment strategies to combat cardiovascular disease in the large portion of the population with risk-altering LRP8 or apoE variants, such as individuals expressing apoE4, who constitute ∼15% of the population (1, 3, 28) . For example, because we now know that a primary consequence of harboring the apoE4 or the ApoER2-R952Q genetic variant is an attenuation in eNOS activation, which leads to a loss of both the reparative and antiinflammatory capacities of the endothelium, such individuals may specifically benefit from treatment with an NO donor (30, 31) . Greater knowledge about apoE and ApoER2 function in endothelium may lead to new therapies to optimize cardiovascular protection in the broader population as well.
Materials and Methods
Cell culture experiments were performed in BAECs, HAECs, 3T3 cells, and mouse primary endothelial cells. Nitric oxide synthase, migration and monocyte adhesion assays were performed using previously reported approaches. Mouse models provided assessments of carotid artery reendothelialization and neointima formation. Details are provided in SI Materials and Methods.
